Vericel (US:VCEL) ZACKSยท2024-11-07 15:11Company Performance - Vericel Corporation reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.05, and an improvement from a loss of $0.08 per share a year ago, representing an earnings surprise of 60% [1] - The company posted revenues of $57.91 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.68%, and showing an increase from year-ago revenues of $45.58 million [2] - Over the last four quarters, Vericel has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Vericel shares have increased approximately 34.9% since the beginning of the year, outperforming the S&P 500's gain of 24.3% [3] - The current consensus EPS estimate for the coming quarter is $0.33 on revenues of $81.48 million, and for the current fiscal year, it is $0.12 on revenues of $240.74 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Vericel belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]